Application of N-substituted derivative with diaminopyrroloquinazoline parent nucleus structure in prevention and treatment of bladder cancer
Through the study of N-substituted derivatives with the parent nucleus structure of diaminopyrroloquinazoline, it was found that its killing ability to bladder cancer cells is better than that of the traditional drug gemcitabine, which solved the problem of poor sensitivity of existing bladder cancer treatment drugs. Provides new directions for the development of anti-bladder cancer drugs.
Patent Information
- Application Number
- CN202411262745.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-12-06
AI Technical Summary
Existing bladder cancer treatment drugs have poor sensitivity to tumor cells, resulting in no response to about half of the cases of bladder cancer, and there is a high risk of recurrence and progression. New target drugs need to be developed to improve the therapeutic effect.
The N-substituted derivative with the parent nucleus of diaminopyrroloquinazoline was used to intervene in the bladder cancer T24 and umuc3 cell lines. The cell survival rate was determined by the CCK-8 method, and half of the inhibitory concentration (IC50) value was calculated. It was found that Its killing ability to bladder cancer cells is better than that of the traditional drug gemcitabine.
The IC50 value of the involved compounds is lower than or close to gemcitabine, indicating that it has strong killing ability to bladder cancer cells, has good therapeutic prospects, and can significantly improve tumor response rate.
Smart Images

Figure BDA0005036233230000021 
Figure BDA0005036233230000031 
Figure BDA0005036233230000041
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine and discloses a new use of an N-substituted derivative with a diaminopyrroloquinazoline mother core structure - anti-bladder cancer activity, which is used for preparing a drug for treating bladder cancer. Background Art
[0002] Bladder cancer is one of the most common malignant tumors of the urinary system. It is mainly divided into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) according to the degree of tumor infiltration. Among them, NMIBC patients account for nearly 80% of the initially diagnosed cases and have a high risk of recurrence and progression. Therefore, chemotherapy-based treatment is an especially important part of the treatment of bladder cancer. Chemotherapy mainly includes intravesical chemotherapy and systemic chemotherapy. Intravesical chemotherapy is mainly used for postoperative intravesical instillation of non-muscle invasive bladder cancer to prevent tumor recurrence. However, due to the heterogeneity of tumors, a certain proportion of tumors are insensitive to drugs, resulting in tumor recurrence. The standard treatment regimen for systemic chemotherapy is the use of cisplatin combined with gemcitabine (GC), but about half of the cases still have no response. Given the differences in sensitivity of different bladder cancer cells to existing drugs, it is particularly important to develop and use drugs with different targets in order to increase the overall tumor response rate.
[0003] The present invention reports the use of an N-substituted derivative with a diaminopyrroloquinazoline nucleus structure in the prevention and treatment of bladder cancer. This type of molecule is formed by the skeleton fusion of the nucleus 3-H-pyrrolo[2,3-c]quinoline ring of the Marinoquinoline alkaloids and the diaminopyrimidine structure. Its usability in the antibacterial field has been confirmed, but its application in the treatment of bladder cancer has not yet been seen. In order to explore new uses for this type of molecule, we tested its inhibitory activity on bladder cancer T24 and umuc3 cell lines. The experimental results further revealed that this type of compound can be developed as a new type of anti-bladder cancer drug. Summary of the invention
[0004] The purpose of the present invention is to provide an N-substituted derivative having a diaminopyrroloquinazoline core structure with anti-bladder cancer activity, in order to prepare a drug for treating bladder cancer.
[0005] The following experiment was conducted by intervening in bladder cancer T24 and umuc3 cell lines and using the CCK-8 method to determine the cell survival rates of T24 and umuc3 cells with different concentrations of intervention, in order to specifically study and analyze the anti-bladder cancer activity of the compound.
[0006] The N-substituted derivatives with a diaminopyrroloquinazoline core structure provided by the present invention are all dissolved and diluted with DMSO to form a 10mM stock solution, and gradiently diluted with RPMI-1640 complete medium as a solvent to form 8μM, 1.6μM, 0.32μM, 0.064μM, 0.0128μM, 0.00256μM, 0.000512μM, 0.0001024μM, 0.00002048μM, and 0.000004096μM working solutions. The cell survival rates of T24 and umuc3 cells with different concentrations of intervention were determined by CCK-8 method, and the half inhibitory concentration (IC50) of each compound in different cells was calculated and fitted according to the cell survival rate. 50 ) value, IC 50 The lower the concentration, the fewer cells survive at the same concentration, which means the stronger the ability to kill tumor cells.
[0007] The bladder cancer cell lines T24 and umuc3 used were cultured in RPMI-1640 complete medium (RPMI-1640 basal medium, 10% fetal bovine serum, penicillin / streptomycin double antibody) at 37° C., 5% carbon dioxide and saturated humidity.
[0008] T24 and umuc3 cells in logarithmic growth phase were digested with trypsin and prepared into single cell suspension using RPMI-1640 complete medium. After counting, they were inoculated into 96-well plates at a density of 5000 cells / well. After the cells adhered to the wall, the culture medium was removed and 100ul / well of the above working solution was added to the plate. Three replicate wells were set up in each group. After 72h of intervention, the working solution was removed and 100ul of RPMI-1640 basal medium containing 5% CCK-8 reagent was added to each well. After further culturing for 2h, the absorbance of each well was measured by a microplate reader at a wavelength of 450nm. The cell inhibition rate and IC were calculated based on the absorbance. 50 . And compared with gemcitabine, a commonly used drug for bladder cancer treatment.
[0009] Each compound was tested three times. The structural formula of the N-substituted derivative having a diaminopyrroloquinazoline core structure and the IC in bladder cancer cells 50 See Table 1.
[0010] Table 1 Structural formula of N-substituted derivatives with diaminopyrroloquinazoline core structure and IC in bladder cancer cells 50 data
[0011]
[0012]
[0013]
[0014]
[0015] The experimental results in Table 1 show that the half inhibitory concentration (IC 50 ) is lower than gemcitabine or close to gemcitabine, that is, the killing ability of the above compounds on bladder cancer cells is better than gemcitabine or similar to gemcitabine. Among them, ZN-18 has the best activity, with IC 50 The values are 0.02971uM and 0.00005274uM, respectively, which are significantly better than gemcitabine. Therefore, the N-substituted derivatives with a diaminopyrroloquinazoline core structure involved in the present invention have good application prospects in the treatment of bladder cancer.
[0016] Based on the above research results, an N-substituted derivative having a diaminopyrroloquinazoline core structure is used as an active substance, and a pharmaceutically acceptable carrier and / or excipient is added in the form of a pharmaceutically acceptable salt to prepare any pharmaceutically acceptable dosage form, such as tablets, sprays, granules, capsules, oral solutions, injections, and suspensions.
Claims
1. Use of an N-substituted derivative having a diaminopyrroloquinazoline core structure as an active ingredient in the preparation of an anti-bladder cancer drug, characterized in that: The structural formula of the compound is as follows:
2. Use of the N-substituted derivative having a diaminopyrroloquinazoline core structure as claimed in claim 1 as an active ingredient in the preparation of an anti-bladder cancer drug, characterized in that: The compound or a pharmaceutically acceptable salt thereof is added to a pharmaceutically acceptable carrier and / or excipient to prepare any pharmaceutically acceptable dosage form.
3. Use of the N-substituted derivative having a diaminopyrroloquinazoline core structure as claimed in claim 2 as an active ingredient in the preparation of an anti-bladder cancer drug, characterized in that: The dosage form is any one of tablets, sprays, granules, capsules, oral liquids, injections, and suspensions.
